Main Article Content

Abstract

Background. The second generation anti-cyclic citrullinated peptide test (CCP2) displays sensitivity comparable to that of rheumatoid factor (RF) (approximately 80%) but with superior specificity (98%) . Several observations have indicated that early rheumatoid arthritis (RA) patients with positive anti-CCP may develop a more erosive disease than those without anti-CCP.

Objective. The purpose of this cross-sectional study was to investigate the correlation between anti-CCP antibodies and clinical and laboratory parameters and radiological joint destruction in RA patients.

Methods. We studied 31 patients with RA fulfilling the 1987 revised criteria of American College of Rheumatology in Rheumatology Clinic of Saiful Anwar General Hospital, Malang, Indonesia. Clinical parameters were collected such as age, sex, visual analog scale,
disease duration and diseases activity score (DAS28-3(CRP)). Laboratory parameters were WBC, hemoglobin, platelet count, erythrocyte sedimentation rate, and Creactive protein. Analyzed autoantibody profiles were RF and anti-CCP (ELISA methode). Radiological joint
destruction was evaluated from bilateral postero-anterior manus x ray (Sharp score).

Results. Anti-CCP antibodies were detected in 48.4% of RA patients with mean antibody concentration was 291.24±143.67 (range 16-523.8) units. Anti CCP level was significantly correlated with duration of RA (month) (p=0.04, r=0.371), RF level (p=0.002, r=0.542) and
Sharp score (p=0.048, r=0.358), but was not significantly correlated with other clinical and laboratory parameters.

Conclusion. Anti-CCP level was correlated with duration of disease, RF, and Sharp score.

Article Details

How to Cite
Suwito, M., Handono, K., Suryana, B. P. P., Kalim, H., & Wahono, C. S. (2018). Correlation between anti-cyclic citrullinated peptide antibodies and the severity of clinical manifestation, laboratory manifestation, and radiological joint destruction in rheumatoid arthritis patients. Indonesian Journal of Rheumatology, 1(2). https://doi.org/10.37275/ijr.v2i1.22

References

  1. Waldenburger JM, Firestein GS. Rheumatoid arthritis: epidemiology,
  2. pathology, and pathogenesis. In: Klippel JH, Stone JH, Crofford LJ,
  3. White PH, editors. Primer on rheumatic diseases. 13th ed. New York:
  4. Springer; 2008. p. 122-31.
  5. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes
  6. JM, Breedveld FC, et al. The diagnostic properties of rheumatoid
  7. arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis
  8. Rheum 2000;43:155-63.
  9. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of
  10. anti-CCP antibodies. Am Clin Lab 2002;21:34-6.
  11. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic
  12. accuracy of the anti citrulline antibody assay for rheumatoid arthritis.
  13. Clin Chem 2001;47:1089-93.
  14. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to
  15. diagnose rheumatoid arthritis early: a prediction model for persistent
  16. (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
  17. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg, D, van de
  18. Stadt RJ, de Koning, Dijkmans BA. Rheumatoid factor and antibodies
  19. to cyclic citrullinated peptide differentiated rheumatoid arthritis from
  20. undifferentiated polyarthritis in patients with early arthritis. J Rheumatol
  21. ;29:2074-6.
  22. Pruijn GJM, Vossenaar ER, Drijfhout JW, van Venrooij WJ, Zendman
  23. AJW. Anti-CCP antibody detection facilitates early diagnosis and
  24. prognosis of rheumatoid arthritis. Current Rheumatology Reviews
  25. ;1:1-7.
  26. van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, GmeligMeyling FH, van Booma-Frankfor C, et al. The prognostic value of
  27. the antiperinuclear factor, anti-citrullinated peptide antibodies and
  28. rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatology
  29. ;17:689-97.
  30. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T.
  31. Prognostic laboratory markers of joint damage in rheumatoid arthritis.
  32. Ann Rheum Dis 2005;64:196-201.
  33. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA,
  34. Breedveld FC, Verweij CL, et al. Auto-antibodies to cyclic citrullinated
  35. peptides predict progression to rheumatoid arthritis in patients with
  36. undifferentiated arthritis: a prospective cohort study. Arthritis Rheum
  37. ;50:709-15.
  38. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
  39. NS, et al. The American Rheumatism Association 1987 revised criteria
  40. for the classification of rheumatoid arthritis. Arthritis Rheum 1988;
  41. :315-24.
  42. Fransen J, Stucki G, van Riel PLCM. DAS28 in rheumatoid arthritis
  43. measures. Arthritis Rheum 2003;49:214-24.
  44. Guerrero AV, Villaseñor CP. Evaluación radiográfica del daño
  45. anatómico en la artritis reumatoide. [Radiographic evaluation of
  46. anatomical damage in rheumatoid arthritis] Revista Colombiana de
  47. Reumatologia 2006;13:214-27.
  48. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Kasper DL, Longo DL,
  49. Braunwald E, Hauser SL, Jameson JL, editors. Harrison’s principle of internal medicine. 17th ed. New York: McGraw-Hill; 2008. p. 2083-92.
  50. Suryana BPP. Faktor-faktor risiko beratnya gangguan fungsional dan
  51. kerusakan sendi secara radiologis pada arthritis rheumatoid. [Risk
  52. factors of the severity of functional impairment and radiological joint
  53. damage in rheumatoid arthritis] Specialist thesis. Brawijaya University;
  54. Shahrir M, Shahdan M, Shahid M, Sulaiman W, Mokhtar AM, Othman
  55. M, et al. Multicentre survey of rheumatoid arthritis patients from
  56. Ministry of Health Rheumatology Centers in Malaysia. Inern Journ of
  57. Rheum Dis 2008;11:287-92.
  58. Wakitani S, Murata N, Toda R, Ogawa R, Kaneshige T, Nishimura Y, et
  59. al. The relationship between HLA-DRB1 alleles and disease subsets
  60. of rheumatoid arthritis in Japanese. Br J rheum 1997;36:630-6.
  61. Serdaroglu M, Cakirbay H, Deger O, Cengiz S, Kul S. The association
  62. of anti-CCP antibodies with disease activity in rheumatoid arthritis.
  63. Rheumatol Int 2008;28:965-70.
  64. Sanmarti R, Gomez A, Ercilla G, Gratacos J, Larrosa M, Suris X, et al.
  65. Radiological progression in early rheumatoid arthritis after DMARDS:
  66. a one-year follow-up study in a clinical setting. Rheumatology
  67. ;42:1044–9.
  68. Vitteqoc O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard
  69. DF, Gayet A, et al. Rheumatoid factor is the strongest predictor
  70. of radiological progression of rheumatoid arthritis in a three-year
  71. prospective study in community-recruited patients. Rheumatology
  72. ;42:939-46.
  73. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben
  74. D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies
  75. in early rheumatoid arthritis: a randomized trial. Ann Intern Med
  76. ;146:406-15.
  77. Jansen LMA, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BAC. Predictors of radiographic joint damage in
  78. patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-7.
  79. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois
  80. A, et al. Anticitrullinated protein/peptide antibody assays in early
  81. rheumatoid arthritis for predicting five year radiographic damage. Ann
  82. Rheum Dis 2003;62:120-6.
  83. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody
  84. test predicts the disease course during years in early rheumatoid
  85. arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
  86. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction
  87. of radiological outcome in early rheumatoid arthritis in clinical
  88. practice: role of antibodies to citrullinated peptides. Ann Rheum Dis
  89. ;63:1090-5.
  90. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients
  91. with rheumatic disease. Ann Rheum Dis 2003;62:870-4.
  92. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value
  93. of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a
  94. systematic literature review. Ann Rheum Dis 2006;65:845-51.
  95. Houssien DA, Jonsson T, Davies E, Scott DL. Rheumatoid factor
  96. isotypes, disease activity and the outcome of rheumatoid arthritis:
  97. comparative effects of different antigens. Scand J Rheumatol
  98. ;27:46-53.
  99. van der Helm-van Mil AHM, Verpoort KN, Breeveld FC, Toes REM,
  100. Huizinga TWJ. Antibodies to citrullinated proteins and differences
  101. in clinical progression of rheumatoid arthritis. Arthritis Res Ther
  102. ;7:949-58.
  103. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke
  104. K. Diagnostic and clinical value of anti-cyclic citrullinated peptide
  105. antibodies compared with rheumatoid factor isotypes in rheumatoid
  106. arthritis. Ann Rheum Dis 2004;63:1079-84.
  107. Vencovsky J, Machacek M, Sedova L, Kafkova J, Gatterova J,
  108. Pesakova V, et al. Autoantibodies can be prognostic markers of
  109. an erosive disease in early rheumatoid arthritis. Ann Rheum Dis
  110. ;62:427-30.
  111. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen
  112. FH, van’t Hof M, et al. The prognostic value of anti-cyclic citrullinated
  113. peptide antibodies in patients with recent-onset rheumatoid arthritis.
  114. Arthritis Rheum 2000;43:1831-5.
  115. De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE,
  116. Veys EM, et al. Rheumatoid factor, but not anti-citrullinated protein antibodies, is modulated by infliximab treatment in Rheumatoid Arthritis.
  117. Ann Rheum Dis 2005;64:299-302.
  118. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies
  119. and rheumatoid factor following anti-TNFα therapy (infliximab) in
  120. rheumatoid arthritis is associated with clinical improvement. Ann
  121. Rheum Dis 2004; 63:1218-21.
  122. Ronnelid J, Wick MC, Lampa J. Longitudinal analysis of citrullinated
  123. protein/peptide antibodies (anti-CP) during 5 year follow up in early
  124. rheumatoid arthritis: anti-CP status predicts worse disease activity and
  125. greater radiological progression. Ann Rheum Dis 2005; 64(12)